American Industrial Partners agreed to acquire Avanos Medical for $1.272 billion in cash, paying $15.25 per share—a 69% premium to the prior close. The all-cash transaction removes a mid-cap medical device manufacturer from public markets after a protracted period of margin compression and strategic ambiguity. Avanos shareholders will receive proceeds within 90 to 120 days, pending regulatory clearance and a shareholder vote expected in Q2 2025.

Avanos manufactures pain management catheters, surgical site infection prevention products, and enteral feeding devices—stable but unspectacular product lines with limited pricing power. Revenue has remained flat near $700 million annually since 2020, while operating margins contracted from 18% to 12% as supply chain costs outpaced ASP gains. The company carries $340 million in net debt, which AIP will refinance through its existing credit facilities. Management had explored strategic alternatives since August 2024, retaining Evercore as sell-side advisor. The final bid valued the enterprise at roughly 2.1x trailing revenue and 14x EBITDA—bottom-quartile for medical device exits but rational given the asset's limited growth profile.

The transaction matters because it confirms that middle-market PE shops are extracting value from publicly traded companies whose equity floats have become operationally expensive relative to their growth. Avanos spent approximately $8 million annually on public company compliance—audit fees, investor relations, board compensation—against an equity market cap that had drifted below $700 million. For a business generating $85 million in EBITDA, that overhead represented nearly 10% of cash flow before any value-creation efforts. AIP specializes in operational restructuring of industrial and healthcare assets with $15 billion in capital under management. The firm will likely consolidate manufacturing footprint, renegotiate supplier contracts under single ownership, and streamline the product portfolio to the highest-margin SKUs. Portfolio companies typically see 200 to 400 basis points of margin expansion within 18 months through procurement and workforce optimization.

Allocators should monitor three follow-on developments. First, whether AIP sells non-core product lines—particularly the chronic care division—within six months to reduce leverage and focus capital on pain management, where Avanos holds stronger competitive positioning. Second, acquisition financing terms, likely a mix of term loans and subordinated notes, will surface within 30 days via credit agreement filings and provide insight into expected cash generation assumptions. Third, watch for management departures: CEO Joe Woody will exit post-close per the merger agreement, and the composition of the new operating team will signal whether AIP plans a hold-and-build strategy or a shorter-duration flip to a strategic acquirer.

The bid arrived at 1.2x book value for a company that had traded below book for most of 2024, underscoring how public market patience for operational turnarounds has evaporated. AIP's thesis rests on the $340 million debt refinancing and margin expansion generating sufficient free cash flow to support a 4x equity return over five years—achievable if the firm extracts 300 basis points of EBITDA margin and exits at 12x to a larger medical device platform. The shareholder vote is scheduled for late May, with an 85% approval threshold already secured via management and board holdings.